(Reuters) - The U.S. Food and Drug Administration said it remained concerned about birth control pills containing the compound drospirenone that might pose higher risk of developing blood clots in women.
The drug regulator said it has completed its review of the two studies evaluating the risk of blood clots in women, but has not reached a conclusion yet.
Germany's Bayer AG's (BAYGn.DE) best-selling birth control drugs, including Yaz and Yasmin, contain the compound.
The agency said it is continuing the review of the compound in a separate FDA-funded study.
Tuesday, September 27, 2011
US FDA remains wary of drospirenone clot risk | Reuters